The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 321.00
Bid: 320.00
Ask: 321.50
Change: 1.00 (0.31%)
Spread: 1.50 (0.469%)
Open: 327.00
High: 329.50
Low: 320.00
Prev. Close: 320.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Axovant FDA meeting feedback

6 Dec 2018 16:11

RNS Number : 7273J
Oxford Biomedica PLC
06 December 2018
 

 

Oxford BioMedica notes Axovant announcement of feedback from FDA regarding AXO-LENTI-PD and progress with ongoing Phase 2 clinical trial

 

Oxford, UK - 06 December 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes an announcement today by Axovant Sciences regarding feedback from a face-to-face pre-IND meeting with the U.S. Food and Drug Administration (FDA) concerning AXO-Lenti-PD for patients with Parkinson's disease. Based on the discussion at the FDA meeting, the totality of data collected on the initial vector construct, ProSavin, including over six years of phase 1/2 clinical data and IND-enabling preclinical data, may be supportive of the planned development programme for AXO-Lenti-PD.

 

In addition, the phase 2 clinical trial of AXO-Lenti-PD (NCT03720418), now called SUNRISE-PD, was initiated in the U.K. in the fourth quarter of 2018. The SUNRISE-PD study is advancing as planned with dosing of the second patient in November 2018. To date, both patients have tolerated the surgical procedure well and were discharged home with no serious adverse events observed. Axovant expects to announce data from the first two patients in March 2019.

 

Under the terms of the agreement with Axovant, Oxford BioMedica received a $30 million upfront payment (approximately £22 million) including $5 million as pre-payment for manufacturing activities related to OXB-102, now renamed AXO-Lenti-PD. Oxford BioMedica is also eligible to receive $55 million upon the achievement of specified development milestones and $757.5 million upon the achievement of specified regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.

 

Read the Axovant press release here

 

 

- Ends -

 

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sarah MacLeod, Head of Communications

 

 

Tel: +44 (0)1865 783 000

 

 

media@oxb.com

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Laura Thornton

Tel: +44 (0)20 3709 5700

 

 

Notes for editors

 

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations and GC LabCell, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com.

 

About AXO-Lenti-PD

AXO-Lenti-PD, also known as OXB-102, is an investigational gene therapy for Parkinson's disease that delivers three genes in vivo via a lentiviral vector to encode a critical set of enzymes required for dopamine synthesis in the brain and is designed to provide patient benefit for many years following a single administration. AXO-Lenti-PD is a next-generation gene therapy designed to further increase endogenous dopamine production over the first-generation product, Prosavin, by modifying the payload configuration. Preclinical studies directly comparing AXO-Lenti-PD to ProSavin demonstrate increased AADC activity and dopamine productivity of the new vector configuration. Oxford BioMedica has successfully completed a phase I/II study for ProSavin®, which met its primary endpoint. The results, which were published in The Lancet in 2014, demonstrate favorable safety and tolerability and a statistically significant improvement from baseline of motor function as measured by the UPDRS Part III score at 6 and 12 months. This improvement has been observed to be sustained in patients for up to six years despite the progressively degenerative nature of Parkinson's disease. Initial data from the ongoing AXO-Lenti-PD clinical program is expected in the first half of 2019.

About Axovant Sciences

Axovant is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating diseases such as Parkinson's disease, oculopharyngeal muscular dystrophy, Duchenne muscular dystrophy, ALS, frontotemporal dementia, and other indications. For more information, visit www.axovant.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGGRUPUPRGQQ
Date   Source Headline
1st May 20247:00 amRNSTotal Voting Rights
30th Apr 20245:00 pmRNS2023 Annual Report and Accounts
29th Apr 20249:38 amRNSPrelim Results for Y/E 2023 - REPLACEMENT
29th Apr 20247:00 amRNSPreliminary results for the year ended 31 Dec 2023
2nd Apr 20247:00 amRNSTotal Voting Rights
20th Mar 20247:00 amRNSUpdate on CDMO Services
11th Mar 20247:00 amRNSBoard Changes
5th Mar 20247:00 amRNSUpdated Financial Guidance and 2023 Trading
1st Mar 20247:00 amRNSTotal Voting Rights
15th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
1st Feb 20244:48 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSBlock Listing Application
30th Jan 20247:00 amRNSTotal Voting Rights
29th Jan 20248:38 amRNSCompletion of Transaction
26th Jan 20243:09 pmRNSBlock listing application
4th Jan 202411:49 amRNSDirector Declaration
2nd Jan 20247:00 amRNSBlock Listing Return
2nd Jan 20247:00 amRNSTotal Voting Rights
13th Dec 20237:00 amRNS2023 AGM Post Meeting Update Statement
7th Dec 20237:00 amRNSBusiness Update
4th Dec 20237:00 amRNSSigning of agreement to acquire ABL Europe
1st Dec 20237:00 amRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of options
16th Nov 20233:32 pmRNSPDMR Dealing – Replacement
14th Nov 20231:43 pmRNSPDMR Dealings
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20236:17 pmRNSHolding(s) in Company
24th Oct 20235:36 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSHolding(s) in Company
11th Oct 202311:33 amRNSPDMR Dealings
4th Oct 20235:09 pmRNSGrant of Options
2nd Oct 20233:06 pmRNSTotal Voting Rights
27th Sep 202312:03 pmRNSPDMR / PCA Dealing
26th Sep 20233:47 pmRNSPDMR Dealings
22nd Sep 202311:42 amRNSPDMR Dealings
20th Sep 202311:42 amRNSDirector Dealings
20th Sep 20237:01 amRNSProject Aquarius
20th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSTotal Voting Rights
22nd Aug 20237:00 amRNSExpanded agreement with Cabaletta Bio
14th Aug 20237:00 amRNSNotice of Interim Results
1st Aug 20237:00 amRNSTotal Voting Rights
3rd Jul 20234:31 pmRNSPDMR Dealings
3rd Jul 20237:00 amRNSOxford Biomedica PLC - Block Listing Return
3rd Jul 20237:00 amRNSTotal Voting Rights
23rd Jun 20235:32 pmRNSResult of AGM
6th Jun 20233:59 pmRNSTotal Voting Rights
15th May 20237:00 amRNSOxford Biomedica launches TetraVecta system

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.